Sign inJoin waitlistJoin the waitlist

Christopher Kanakry

Senior Investigator · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Clinical Center at the National Institutes of Health
Present

Johns Hopkins University School of Medicine
Internal Medicine
Duke University School of Medicine
Harvard College

Research

Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide
Science Translational Medicine · 2013 · First of 10 authors · 303 citations
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Blood · 2015 · 255 citations
Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
Journal of Clinical Investigation · 2019 · Last of 6 authors · 254 citations

Jennifer Kanakry
30 papers
Leo Luznik
26 papers
DD
Dimana Dimitrova
16 papers
EF
Ephraim Fuchs
14 papers
Daniel Weisdorf
12 papers
Rohtesh Mehta
12 papers
TN
Taiga Nishihori
12 papers
Hillard Lazarus
11 papers
JM
Javier Meade
11 papers
Shannon McCurdy
11 papers
Michael Grunwald
10 papers
Mustafa Hyder
10 papers

Grants

Deciphering the Efficacy of Posttransplant Cyclophosphamide in BMT
National Cancer Institute · ZIA
Contact PI · $18.5M · Division of Basic Sciences - Nci

Clinical trials

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Principal investigator · Recruiting
National Cancer Institute (NCI)
2026–2028
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2034
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2028
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2029